Brief: Qlife Signs Agreement With Chinese Hipro Biotechnology
Dec 5 (Reuters) - Qlife Holding AB QLIFE.ST :
* QLIFE HOLDING AB - CHINESE ENTRY TO PAVE THE WAY IN
DENMARK
* QLIFE HOLDING AB - HAS SIGNED AN AGREEMENT WITH CHINESE
HIPRO
BIOTECHNOLOGY FOR PRODUCTION, MARKETING AND SALE OF THEIR EGOO
TEST SYSTEM IN CHINA
Source text for Eikon: ID:nWkr9mFJNd
Further company coverage: QLIFE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Qlife Holding AB
See all newsAdvisory: Alerts on Qlife's agreement with global pharma company withdrawn
Brief: Qlife Holding Enters Feasibility Deal With Pharma Co For Egoo Health Biomarker
Brief: Qlife Holding Q1 EBITDA Loss SEK 5.5 Mln
Sweden's Qlife Q1 revenue drops, losses widen slightly
Brief: Qlife Holding Q4 EBITDA At SEK -1.6 Million